EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Safety and Clinical Outcomes of High‐ Versus Low‐Dose Oral Peanut Immunotherapy in Polish Children With Peanut Allergy

Klementyna Łyżwa iD, Magdalena Chojnowska-Wójtowicz, Wioletta Zagórska, Marek Kulus iD, Katarzyna Grzela iD

Acta Paediatrica · 2026-12 · 115 (12) · 2862-2871

DOI: 10.1111/apa.70704 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Acta Paediatrica, online erschienen am 05.08.2026. Verfasst von Klementyna Łyżwa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Pulmonology and Allergology, Medical University of Warsaw, Warsaw, Poland. Hauptthemen laut MEDLINE: Peanut Hypersensitivity, Desensitization, Immunologic. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To compare safety and clinical outcomes of two different oral immunotherapy (OIT) maintenance doses (150 mg vs. 300 mg) of peanut protein in children with peanut allergy.

Methods

This prospective study enrolled 44 children aged 4–17 years with confirmed peanut allergy. Following dose escalation, participants were allocated to receive either 150 or 300 mg of peanut protein daily for 8 weeks. Oral food challenges (OFCs) were conducted before and after OIT. The primary endpoint was the proportion of participants tolerating ≥ 300 mg of peanut protein post‐treatment. Secondary outcomes included changes in immunologic markers (skin prick tests wheal size, sIgE, IgG4) and safety.

Results

Of the 44 enrolled children, 33 (75.0%) completed the full protocol. The primary outcome was achieved in 73.9% of the 150 mg group and 71.4% of the 300 mg group ( p = 0.853). Both regimens were associated with reductions in immunological parameters. Adverse events were mainly mild to moderate.

Conclusion

Peanut OIT using either 150 mg or 300 mg maintenance doses was associated with increased tolerance thresholds and immunological changes in highly allergic children. These findings support the feasibility of OIT in real‐world clinical settings while highlighting the need for further multicentre research to determine optimal dosing strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peanut HypersensitivityDesensitization, ImmunologicHumansChildFemaleChild, PreschoolMaleProspective StudiesAdministration, OralAdolescentTreatment OutcomePolandArachis

Stichwörter der Autor:innen

childrenfood allergyoral immunotherapypeanut

Autor:innen und Institutionen

  • Department of Paediatric Pulmonology and Allergology, Medical University of Warsaw, Warsaw, Poland.
  • Startmed Medical Center, Lomianki, Poland.

ORCID-Profile: Klementyna Łyżwa, Marek Kulus, Katarzyna Grzela

Zitieren

APA

Łyżwa, K., Chojnowska-Wójtowicz, M., Zagórska, W., Kulus, M., & Grzela, K. (2026). Safety and Clinical Outcomes of High‐ Versus Low‐Dose Oral Peanut Immunotherapy in Polish Children With Peanut Allergy. Acta Paediatrica, 115(12), 2862-2871. https://doi.org/10.1111/apa.70704

Vancouver

Łyżwa K, Chojnowska-Wójtowicz M, Zagórska W, Kulus M, Grzela K. Safety and Clinical Outcomes of High‐ Versus Low‐Dose Oral Peanut Immunotherapy in Polish Children With Peanut Allergy. Acta Paediatrica. 2026;115(12):2862-2871. doi:10.1111/apa.70704

BibTeX
@article{ywa2026,
  author = {Łyżwa, Klementyna and Chojnowska-Wójtowicz, Magdalena and Zagórska, Wioletta and Kulus, Marek and Grzela, Katarzyna},
  title = {Safety and Clinical Outcomes of High‐ Versus Low‐Dose Oral Peanut Immunotherapy in Polish Children With Peanut Allergy},
  journal = {Acta Paediatrica},
  year = {2026},
  volume = {115},
  number = {12},
  pages = {2862--2871},
  doi = {10.1111/apa.70704}
}
Kostenlos starten →